株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

急性骨髄性白血病 (AML):世界の治験動向

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017

発行 GlobalData 商品コード 212838
出版日 ページ情報 英文 1827 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.80円で換算しております。
Back to Top
急性骨髄性白血病 (AML):世界の治験動向 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017
出版日: 2017年02月28日 ページ情報: 英文 1827 Pages
概要

当レポートでは、急性骨髄性白血病 (AML) 治療薬に関する治験の最新動向について分析し、疾患の概要を初め、G7諸国・E7諸国における治験の状況、地域・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んでお届けします。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要5カ国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:癌治療薬の治験における急性骨髄性白血病 (AML) の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:癌治療薬の治験における急性骨髄性白血病 (AML) の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

急性骨髄性白血病 (AML) 治療薬の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース

治験プロファイルの概要

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC4080CTIDB

GlobalData's clinical trial report, "Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 5
  • List of Figures 5
  • Report Guidance 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Five Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 19
  • Clinical Trials in G7 Countries by Trial Status 20
  • Clinical Trials by E7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials 21
  • Clinical Trials by Phase in E7 Countries 23
  • Clinical Trials in E7 Countries by Trial Status 24
  • Clinical Trials by Phase 26
  • In Progress Trials by Phase 27
  • Clinical Trials by Trial Status 28
  • Clinical Trials by End Point Status 30
  • Subjects Recruited Over a Period of Time 31
  • Clinical Trials by Sponsor Type 32
  • Prominent Sponsors 33
  • Top Companies Participating in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials 35
  • Prominent Drugs 37
  • Latest Clinical Trials News on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) 39
  • Feb 23, 2017: Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia 39
  • Feb 23, 2017: Children's National Health System Experts Present Data on Novel Approach to Cell Therapy for Cancer Patients 40
  • Feb 17, 2017: Immune Pharmaceuticals Announces the launch of REMAIN, an international Overall Survival study with Ceplene and low dose Proleukin in REmission MAINtenance in Acute Myeloid Leukemia 40
  • Feb 13, 2017: Actinium Pharmaceuticals Presents Data On Actimab-A At BIO CEO & Investor Conference 41
  • Feb 06, 2017: FDA Grants Cellectis IND Approval to Proceed with the Clinical Development of UCART123, the First Gene Edited Off-the-Shelf CAR T-Cell Product Candidate developed in the U.S. 41
  • Feb 06, 2017: INNATE PHARMA announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab 41
  • Feb 02, 2017: Trillium Therapeutics Provides Update On TTI-622 42
  • Jan 11, 2017: Regenacy Pharma's HDAC1 Inhibitor ACY-957 Demonstrates Potent Anti-Leukemic Activities 42
  • Jan 11, 2017: Regenacy Pharma's HDAC2 Inhibitor ACY-1035 Demonstrates Potent Anti-Leukemic Activities 43
  • Jan 09, 2017: Syros Pharma Outlines 2017 Strategic Goals, Provides Update On SY-1425 43
  • Jan 05, 2017: Mirati Therapeutics Provides Update On Cancer Pre-Clinical Program 44
  • Jan 03, 2017: Cellectis Submits IND Application for UCART123, an Allogeneic Gene Edited CAR T-Cell Product Candidate, in AML and BPDCN 44
  • Dec 28, 2016: argenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental Medicine 45
  • Dec 27, 2016: Seattle Genetics Announces Clinical Hold on Several Phase 1 Trials of Vadastuximab Talirine (SGN-CD33A) 45
  • Dec 23, 2016: Anti-AXL Biologic Increases Tumor Sensitivity to Radiation and Check-Point Inhibitors 46
  • Dec 19, 2016: Kancera reports positive results for fractalkine blocker KAN0440567 in preclinical models of pain caused by anti-cancer drugs 46
  • Dec 15, 2016: Cellectis Announces Recombinant DNA Advisory Committee's (RAC) Unanimous Approval of UCART123 Phase 1 Study Protocols in AML and BPDCN 47
  • Dec 07, 2016: Personalized Cancer Vaccine is Associated With Promising Outcomes for Patients with Acute Myeloid Leukemia 47
  • Dec 06, 2016: Oncternal Therapeutics Presented Data on TK216 at American Society of Hematology Meeting 48
  • Dec 06, 2016: Stemline Therapeutics Presents SL-401 Lead-in Results from its Ongoing Phase 2 Trial in AML in Remission with MRD and Phase 2 Trial in High-Risk Myeloproliferative Neoplasms (MPN) at ASH 48
  • Dec 06, 2016: Mateon Announces Presentation of OXi4503 AML Study Data at 58th Annual Meeting of American Society of Hematology 49
  • Dec 06, 2016: Immunotherapy shows promise in preventing leukemia relapse 49
  • Dec 06, 2016: Celyad Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting 50
  • Dec 05, 2016: Agios Announces New Clinical Data from Dose-Escalation Portion of Phase 1 Trial of Single Agent AG-120 Showing Durable Molecular Responses in Patients with Advanced Hematologic Malignancies 50
  • Dec 05, 2016: Karyopharm Presents Updated Phase 1b STOMP Data at the American Society of Hematology 2016 Annual Meeting 51
  • Dec 05, 2016: Sunesis Pharmaceuticals Announces Presentation of Updated Results from the VALOR Trial Examining Overall Survival in Patients Age 60 Years and Older with Relapsed/Refractory AML at the ASH Annual Meeting 53
  • Dec 05, 2016: Daiichi Sankyo Presents Phase 1 Data for MDM2 Inhibitor DS-3032 in Acute Myeloid Leukemia and Myelodysplastic Syndrome at the 58th Annual Meeting of the American Society of Hematology 54
  • Dec 05, 2016: BerGenBio Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML at ASH 2016 54
  • Dec 05, 2016: Bellicum Pharmaceuticals Announces GoCAR-T and GoTCR Preclinical Presentations at the American Society of Hematology 2016 Annual Meeting 55
  • Dec 05, 2016: Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy with HMAs, in Patients with Acute Myeloid Leukemia at ASH Annual Meeting 56
  • Dec 05, 2016: BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016 57
  • Dec 05, 2016: Preclinical Data on IMGN632, a Novel CD123-Targeting ADC, Presented at ASH Annual Meeting 58
  • Dec 05, 2016: Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 58
  • Dec 05, 2016: Syros Pharmaceuticals Presents Data at ASH Annual Meeting Further Supporting Clinical Potential of Its First-in-Class Selective RARa Agonist for Genomically Defined Subsets of AML and MDS Patients 59
  • Dec 05, 2016: Actinium Highlights Results from Phase 1 Clinical Trial of Actimab-A at 58th American Society of Hematology Annual Meeting 60
  • Dec 05, 2016: Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at 2016 ASH Annual Meeting 60
  • Dec 05, 2016: Cornerstone Pharmaceuticals Presents Phase I Data on CPI-613 in Acute Myeloid Leukemia (AML) and T-Cell Non-Hodgkin Lymphoma (T-cell NHL) at ASH 2016 61
  • Dec 05, 2016: ORYZON Announces Encouraging Top-line Results from Phase I-IIA Clinical Trial in Acute Leukemia of RG6016 (ORY-1001) at the American Society of Hematology 2016 Annual Meeting 62
  • Dec 04, 2016: Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting 63
  • Dec 03, 2016: New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome 64
  • Dec 03, 2016: Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting 64
  • Dec 03, 2016: Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting 65
  • Dec 02, 2016: Calithera Biosciences Announces CB-839 Preclinical Data Selected for Presentation at the 58th American Society of Hematology Annual Meeting 66
  • Dec 02, 2016: Stemline Announces Seven Presentations, Including Oral Presentation of Updated SL-401 Phase 2 BPDCN Data, at the 2016 ASH Meeting this Weekend 66
  • Dec 01, 2016: ERYTECH Presents New Data on GRASPAs Mechanism of Action at ASH Annual Meeting 67
  • Dec 01, 2016: argenx to provide update on ARGX-110 during American Society of Hematology Annual Meeting 68
  • Nov 29, 2016: New Research Validates both Single Agent and Synergistic Anticancer Activity for Aravive Biologics' Anti-AXL Candidate in Multiple Tumor Types 69
  • Nov 29, 2016: Actinium Further Strengthens Clinical Development Team with Senior Hire to Support Later-Stage Clinical Trials 69
  • Nov 29, 2016: Astex to Showcase Its Next-Generation Hypomethylating Agent Being Developed for Treatment of AML/MDS at the 2016 Annual Meeting of the American Society of Hematology 70
  • Clinical Trial Profile Snapshots 71

Appendix 1822

  • Abbreviations 1822
  • Definitions 1822
  • Research Methodology 1824
  • Secondary Research 1825
  • About GlobalData 1826
  • Contact Us 1826
  • Disclaimer 1826
  • Source 1827

List of Tables

List of Tables

  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Region, 2017* 8
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 15
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16
  • Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2017* 18
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2017* 22
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase, 2017* 26
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 27
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 29
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 32
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 34
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 36
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 38

List of Figures

List of Figures

  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 15
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16
  • Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2017* 17
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2017* 21
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 26
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 27
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 32
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37
  • GlobalData Methodology 1824
Back to Top